Equity · Healthcare
MDGL
NASDAQMadrigal Pharmaceuticals (MDGL)
The line runs 450 USD on 16 October through 399.83 USD on 6 November, on a scale from 375 to 475. Days the market did not trade hold the previous close, flat.
- Market cap
- 9.3B USD
- Revenue, year to Dec 2025
- 958.4M USD
- EPS, diluted, year to Dec 2025
- −10.15 USD
- 52-week range
- 396.06 USD – 604 USD
- Avg volume
- 84.7K
- Mentions, 30 days
- 2
as of Nov 6, 2026
Have Madrigal Pharmaceuticals (MDGL) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Madrigal Pharmaceuticals insiders reported 4 open-market sales and 2 purchases (SEC Form 4).
Form 4, 90 days to 10 Nov 2026, newest reported trade 6 Nov 2026
Buys 2Sells 4Net bought $28.01MOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 06 Nov 2026 | Kelley Shannon TGeneral Counsel | Sell | 1,077 | 431K USD |
| 06 Nov 2026 | BAKER BROS. ADVISORS LPDirector | Buy | 76,140 | 29.3M USD |
| 04 Nov 2026 | BAKER BROS. ADVISORS LPDirector | Buy | 15,666 | 5.8M USD |
| 11 Sep 2026 | Sibold William JohnPresident and CEO | Sell | 5,221 | 2.8M USD |
| 09 Sep 2026 | Sibold William JohnPresident and CEO | Sell | 6,362 | 3.4M USD |
| 17 Aug 2026 | Kelley Shannon TGeneral Counsel | Sell | 664 | 342K USD |
| Bought | 2 open-market purchases | 91,806 | $35.02M | |
| Sold | 4 open-market sales | 13,324 | $7.01M |
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Aug 2026 | REED JOHN CDirector | Award | 647 |
Which funds hold Madrigal Pharmaceuticals (MDGL)?
11 of the 45 institutional funds we track reported a Madrigal Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 1.7B USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Baker Bros. Advisors | Held (±25%) | 2,143,131 | 1.2B USD | +0.1% |
| Citadel Advisors | Held (±25%) | 507,233 | 272.4M USD | +11.8% |
| Point72 Asset Management | Trimmed | 137,029 | 73.6M USD | −39.2% |
| Marshall Wace | Added | 101,859 | 54.7M USD | +365.1% |
| Millennium Management | Added | 81,196 | 43.6M USD | +98.8% |
| Balyasny Asset Management | New position | 79,011 | 42.4M USD | |
| Renaissance Technologies | Trimmed | 45,942 | 24.7M USD | −36.1% |
| D. E. Shaw & Co. | Held (±25%) | 35,071 | 18.8M USD | +16.4% |
| AQR Capital Management | Held (±25%) | 15,827 | 8.5M USD | −0.8% |
| Tudor Investment Corp | Held (±25%) | 11,509 | 6.2M USD | −1.0% |
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Have members of Congress traded Madrigal Pharmaceuticals (MDGL)?
The most recent congressional trade disclosed in Madrigal Pharmaceuticals is a sale by Daniel S. Goldman (house, NY), dated 10 Apr 2023.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 10 Apr 2023 | Daniel S. Goldmanhouse · Democrat–NY | Sale | 1K USD–15K USD | 39 days |
What has been filed or recorded for Madrigal Pharmaceuticals (MDGL)?
The filings we hold for Madrigal Pharmaceuticals, newest first: 3 fails-to-deliver days, 7 quarterly earnings reports and 5 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 22 shares | 10K USD notional · <0.001% of shares out |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 22 shares | 11K USD notional · <0.001% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 32,700 shares | 16.2M USD notional · 0.142% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 1.83 USD | |
| 30 Sep 2026 | Financials | Total assets | 1.4B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 626.9M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −1.99 USD | |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −3.25 USD | |
| 31 Dec 2025 | Quarterly earnings | Q3 2026 reported | EPS −10.15 USD | |
| 31 Dec 2025 | Financials | Revenue | 958.4M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −288.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −10.15 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −4.01 USD | |
| 30 Jun 2025 | Quarterly earnings | Q1 2026 reported | EPS −1.50 USD | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −2.61 USD | Revenue $137M |
What is Reddit saying about Madrigal Pharmaceuticals (MDGL)?
Reddit mentioned MDGL 2 times in the 30 days to 9 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 9 November 2026.
30-day window, Method
Mentions, 30 days 2Communities 1
How do Reddit mentions of Madrigal Pharmaceuticals (MDGL) compare with its price?
Share ↗
Where Madrigal Pharmaceuticals (MDGL) is discussed
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/stocks | 100% | 2 | +0.08 |
The threads carrying the mentions
30 days, shown as posted
| Thread | Community | Mentions | Latest |
|---|---|---|---|
| Novo Nordisk (NVO) and Madrigal (MDGL) both have something at stake in a new low-dose semaglutide comboby u/ohdonpier | r/stocks | 2 | 3 weeks ago |
Live discussion on Reddit, shown as posted. Titles link to the original threads.
Madrigal Pharmaceuticals (MDGL): frequently asked questions
What did Madrigal Pharmaceuticals shares close at?
Madrigal Pharmaceuticals closed at 399.83 USD on 6 Nov 2026, down 0.18% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Madrigal Pharmaceuticals’ market cap?
Madrigal Pharmaceuticals is worth 9.3B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Madrigal Pharmaceuticals’ revenue?
Madrigal Pharmaceuticals reported revenue of 958.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Madrigal Pharmaceuticals insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Madrigal Pharmaceuticals insiders reported 4 open-market sales and 2 purchases (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Madrigal Pharmaceuticals?
11 of the 45 funds we track reported a Madrigal Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, Citadel Advisors and Point72 Asset Management. See Funds
Have members of Congress traded Madrigal Pharmaceuticals?
Yes. 1 trade in Madrigal Pharmaceuticals appears in the congressional disclosures we hold: a sale by Daniel S. Goldman (House, NY) dated 10 Apr 2023, filed 19 May 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Madrigal Pharmaceuticals last report earnings?
Madrigal Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 1.83 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals was mentioned 0 times in the last 7 days across the finance subreddits we track, and 2 times over the trailing 30 days. Of the 2 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings